MediPost Confirms Efficacy in Phase 1 Clinical Trial of High-Potency Stem Cell Therapy
[Asia Economy Reporter Ji Yeon-jin] Medipost announced on the 22nd that it has confirmed the safety and exploratory efficacy of 'SMUP-IA-01' in a domestic Phase 1 clinical trial targeting patients with knee osteoarthritis.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
SMUP-IA-01 is a high-potency allogeneic umbilical cord blood-derived mesenchymal stem cell therapy. The company plans to conduct a 5-year long-term follow-up clinical study on the trial participants of Phase 1, while also applying for Phase 2 clinical trials with the Ministry of Food and Drug Safety of Korea.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
